

# Lydia Gaba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5697014/publications.pdf>

Version: 2024-02-01

29  
papers

1,435  
citations

840585

11  
h-index

677027

22  
g-index

31  
all docs

31  
docs citations

31  
times ranked

3359  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors. <i>Diagnostics</i> , 2022, 12, 226.	1.3	14
2	SEOM-GEICO clinical guidelines on endometrial cancer (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 625-634.	1.2	11
3	AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancerâ€”A multicenter, randomized, phase III trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5612-TPS5612.	0.8	5
4	Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17598-e17598.	0.8	0
5	Clinical insights from the rucaparib access program in Spain: A sub-analysis of long-term responders by GEICO.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17562-e17562.	0.8	0
6	A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2021, 146, 87-94.	1.3	12
7	Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma. <i>Journal of Immunotherapy</i> , 2021, 44, 204-207.	1.2	2
8	Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3060-3060.	0.8	0
9	ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5612-TPS5612.	0.8	0
10	Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. <i>Cancers</i> , 2021, 13, 3776.	1.7	5
11	Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix. <i>Modern Pathology</i> , 2020, 33, 128-137.	2.9	23
12	Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO). <i>Gynecologic Oncology Reports</i> , 2020, 33, 100594.	0.3	10
13	Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6050-6050.	0.8	20
14	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018, 91, 116-124.	1.3	69
15	Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabineâ€”erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 935-943.	1.1	10
16	Immune-Related Gene Expression Profiling After PD-1 Blockade in Nonâ€”Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017, 77, 3540-3550.	0.4	327
17	Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. <i>Muscle and Nerve</i> , 2017, 56, E162-E167.	1.0	18
18	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 1777-1786.	2.9	58

#	ARTICLE	IF	CITATIONS
19	Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 66-66.	0.8	0
20	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. <i>ESMO Open</i> , 2016, 1, e000032.	2.0	7
21	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 709-713.	0.9	63
22	High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14552-e14552.	0.8	0
23	Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3038-3038.	0.8	0
24	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015, 24, S26-S35.	0.9	735
25	Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2585-2585.	0.8	4
26	Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9069-9069.	0.8	15
27	Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 10604-10616.	0.8	21
28	Clinical outcomes in BRAFV600-mutant metastatic melanoma with sequential treatment with immunotherapy and BRAF inhibitors or vice versa.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20030-e20030.	0.8	0
29	Unscheduled visits in cancer patients treated in a clinical trials unit (CTU).. <i>Journal of Clinical Oncology</i> , 2013, 31, e17580-e17580.	0.8	0